Bayer has responded to its current woes by going all in on cell therapy – a move that, even if successful, will take a long time to pay off.
Reata Pharmaceuticals will soon find out if its decision to persevere with omaveloxolone despite an earlier failure has paid off.
Atara tackles multiple sclerosis’s virus hypothesis while Aslan needs to roar with crucial biliary tract cancer data.
Medtronic decides that Solitaire is best played with a partner.
One of the biggest drugs of the year, Abbvie’s Jak inhibitor upadacitinib, could get the nod in August.
The company has quietly emerged as the key player to watch in an area that has seen several setbacks of late.
In the wake of a clinical trial failure Marinus plays down oral ganaxolone, but investors are unimpressed.
Acadia has tried to see the positives after a pivotal trial failure with Nuplazid in schizophrenia, but the data bode ill for other label-expansion studies.
A strong second quarter pushed Novartis’s stock up 5% this morning, but Kymriah continues to look weak, and the jury is still out on Zolgensma.